Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK043 + Firmonertinib in EGFRm+ NSCLC
NCT06668103Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lumipodlin in non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicity at 21 days, Adverse Events at 30 months and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
lumipodlin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06668103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668103.